Precision Therapeutics plans to launch Med BioGene's LungExpress Dx molecular diagnostic by mid-year, the companies announced this week.
Precision Therapeutics Assesses Multi-Gene Predictors of Breast Cancer Chemo Response
NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Tuesday that it has revised its co-marketing deal with Precision Therapeutics.
NEW YORK (GenomeWeb News) – Med BioGene today announced it has amended its commercialization agreement with Precision Therapeutics for Med Bio's LungExpress Dx test.
NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.
Precision Therapeutics' BioSpeciFx
Med BioGene's shareholders have approved the deal, which gives Precision rights to commercialize Med BioGene's gene expression-based test for early stage non-small-cell lung cancer.
Precision Therapeutics made an improved offer, matching the upfront payment offered by Signal Genetics to license the LungExpress Dx technology.
The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.
Precision Therapeutics has gained exclusive rights to the LungExpress Dx test.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.